FDA Grants Priority Review for Agios' Sickle Cell Drug Mitapivat, PDUFA Date Set for Nov 1
AGIO sits 70% above its 52-week low of $22.24.
Summary
The U.S. FDA has granted Priority Review to Agios' supplemental New Drug Application (sNDA) for mitapivat in sickle cell disease, setting a PDUFA goal date of November 1, 2026. This accelerates the review process from 10 to 6 months, signaling the FDA's view that mitapivat could offer significant improvements for this serious condition. This positive regulatory step follows the detailed Phase 3 RISE UP trial results for mitapivat in sickle cell disease presented in June. An approval would significantly expand the market for mitapivat, which is already approved for other hemolytic anemias.
At the time of this announcement, AGIO was trading at $37.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $22.24 to $46.00. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.